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4-Hydroxynonenal (HNE) is a cytotoxic and genotoxic lipid oxidation secondary product which is formed
endogenously upon peroxidation of cellular n-6 fatty acids.
However, it can also be formed in food or during digestion, upon peroxidation of dietary lipids.
Several studies have evidenced that we are exposed through food to signiﬁcant concentrations of HNE
that could pose a toxicological concern. It is then of importance to known how HNE is metabolized after
oral administration. Although its metabolism has been studied after intravenous administration in order
to mimick endogenous formation, its in vivo fate after oral administration had never been studied.
In order to identify and quantify urinary HNE metabolites after oral administration in rats, radioactive
and stable isotopes of HNE were used and urine was analyzed by radio-chromatography (radio-HPLC)
and chromatography coupled with High Resolution Mass Spectrometry (HPLC–HRMS).
Radioactivity distribution revealed that 48% of the administered radioactivity was excreted into urine
and 15% into feces after 24 h, while 3% were measured in intestinal contents and 2% in major organs,
mostly in the liver. Urinary radio-HPLC proﬁles revealed 22 major peaks accounting for 88% of the ur-
inary radioactivity. For identiﬁcation purpose, HNE and its stable isotope [1,2-13C]-HNE were given at
equimolar dose to be able to univocally identify HNE metabolites by tracking twin peaks on HPLC–HRMS
spectra. The major peak was identiﬁed as 9-hydroxy-nonenoic acid (27% of the urinary radioactivity)
followed by classical HNE mercapturic acid derivatives (the mercapturic acid conjugate of di-hydro-
xynonane (DHN-MA), the mercapturic acid conjugate of 4-hydroxynonenoic acid (HNA-MA) in its
opened and lactone form) and by metabolites that are oxidized in the terminal position. New urinary
metabolites as thiomethyl and glucuronide conjugates were also evidenced. Some analyses were also
performed on feces and gastro-intestinal contents, revealing the presence of tritiated water that could
originate from beta-oxidation reactions.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
4-Hydroxynonenal (HNE) is an α,β-unsaturated aldehydic sec-
ondary lipid peroxidation product, arising from omega-6 poly-
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.numerous pathological states in which its generation is a con-
sequence of oxidative stress accompanying inﬂammatory events.
However, this product is not only a mere product of lipid perox-
idation: it is a reactive compound that can play a biological role or
have cytotoxic and genotoxic properties, depending on its con-
centration, through covalent attachment to macromolecules.
In addition to its endogenous formation, HNE can be found in
various foodstuffs, upon non enzymatic oxidation of dietary PUFAs
due to an imbalance between pro- and anti-oxidant compounds,
or due to food-processing oxidation during cooking or storage.
Seppanen and Csallany have reported HNE formation in thermally
oxidized oils, and its presence in food fried in those oils to a
concentration reaching 600 mg/kg of oil [1,2]. HNE can be found in
meat products, or in ﬁsh in concentration reaching 5 mg/kg in case
of prolonged storage [3,4] and in PUFA fortiﬁed infant formula andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
J. Keller et al. / Redox Biology 4 (2015) 136–148 137baby food (up to 0.8 mg/kg, 10 days after package opening) [5]. Our
group has shown that heme iron concentration may have a pro-
minent role [6].
Several studies have evidenced the oral toxicity of HNE. Nish-
ikawa et al. reported an acute toxicity of HNE after a single dose
given by gavage (from 10 to 1000 mg/kg BW). They observed a
diffuse liver cell necrosis 14 days after the treatment in all treated
animals, while rats that died few hours after the 1000 mg/kg
dosing presented extensive kidney tubular necrosis [7]. They
concluded that HNE administered at high dose can induce lethal
renal damage before severe hepatic damage occurs. Such hepato-
toxicity was reported after injection in the portal vein of 4-hy-
droxy-hexenal (HHE), an analog of HNE formed upon omega-3
PUFAs [8]. Chung et al. reported a liver tumorigenic activity of
crotonaldehyde, another α, β-unsaturated aldehyde, after oral
exposure in drinking water for 113 weeks. Wacker et al. [9] re-
ported a slight increase of HNE speciﬁc propano-adducts in for-
estomach DNA in rats treated with single oral dose of HNE
(500 mg/kg BW). Kang et al. reported nephro-and hepatotoxicity
of HNE after 4 weeks of daily dose ranging from 0.5 to 12.5 mg/kg
BW [10]. From this study, these authors have calculated a no-ad-
verse-effect-level (NOAEL) below 0.5 mg/kg/day for HNE.
Taken together, those studies show that we are exposed
through food to signiﬁcant concentrations of HNE that could pose
a toxicological concern. It is then of importance to known how
HNE is metabolized after oral administration. If some studies have
been done, by our group [11,12] and others [13,14], on the in vivo
metabolism of HNE or HHE after parenteral administration, none
has been achieved to elucidate oral fate of HNE.
In the present work, we used a strategy based on both radio-
active (i.e. [4-3H]-HNE) and stable (i.e. [1,2-13C]-HNE) isotope la-
beling to elucidate its oral metabolic fate, that is to say to identify
and quantify the major HNE metabolites in urine.Material and methods
Chemicals
Reagents were purchased from Sigma-Aldrich (France). Sol-
vents for HPLC were of analytical grade and purchased from Fisher,
France. Ultrapure water from MilliQ system (gradient A10, Milli-
pore) was used for HPLC.
[4-3H]-4-Hydroxynon-2(E)-enal (3H-HNE) was obtained by acid
hydrolysis of aldehyde protected diethyl acetal precursor, synthe-
sized as previously described [15], and puriﬁed by thin layer
chromatography (Fig. 1). The synthesis was carried out at CEA,
Service des Molecules Marquees, CEN, Saclay, France. Radio-
chemical purity (495%) was checked by HPLC before adminis-
tration to rats. Speciﬁc activity was 222 GBq/mol
[1,2-13C2]-4-Hydroxynon-2(E)-enal (13C-HNE) (Fig. 1): 13C-HNE
was prepared from ethyl [1,2-13C2]-2-bromoacetate according to
our published method [16], with modiﬁcations as previously de-
scribed [17]. 4-Hydroxynon-2(E)-enal (HNE): HNE was prepared
from ethyl 2-bromoacetate by the same method as for 13C-HNE.
4,9-dihydroxy-2-nonenoic acid (9-hydroxy-HNA) standard was
obtained as previously described [12]. 1,4-dihydroxynonane mer-
capturic acid (DHN-MA) and 4-hydroxynonanoic mercapturic acid
(HNA-MA) standards were synthesized as previously described
[11].
Animal treatments
Male Wistar rats (200 g) were purchased from Charles River.
Animal care was in accordance with our local ethic committee
(number TOXCOM/0008/FG). 3 Rats were treated by gavage with0.9 ml of an equimolar mixture of HNE and 13C-HNE and of
3H-HNE diluted in water. 3 Other rats were treated by gavage with
1 ml of the same mixture of 12C-HNE and 13C-HNE diluted in water,
without radiolabeled HNE. These treatments contained 1 mg/ml of
HNE, 1 mg/ml of 13C-HNE and, when appropriate, 0.97 MBq/ml of
3H-HNE. HNE concentration was checked spectrophotometrically
(λ, 223 nm; ε, 13,750 l/mol/cm).
The rats were housed in individual metabolism cages and food
(A03 breeding diet, SAFE, France) and tap water were provided ad
libitum. 24 h Feces and 0–6 h and 6–24 h urine were collected.
Rats were sacriﬁced by CO2 inhalation. Several organs and tissues
were collected and stored at  80 °C until analysis. Organs and
tissues coming from rats treated with radiolabeled HNE were used
for distribution of radioactivity and radio-HPLC analyses. Urine of
rats treated with HNE and 13C-HNE mixture only was used for
HPLC/HRMS analyses (1st set of experiments, Fig. 2). For radio-
HPLC analyses followed by MS/MS analyses (2nd set of experi-
ments, Fig. 2), a mixture of radioactive (1/3) and non radioactive
(2/3) urine was used, in order to be able to detect radioactive
peaks but to avoid an important radioactive contamination of
mass spectrometry equipment.
Radioactivity determination
Radioactivity was counted PerkinElmer Tri-carb 2910 TR liquid
scintillation analyzer (PerkinElmer, France), using Ultima Gold
(PerkinElmer) as scintillation cocktail. Urine was analyzed directly,
while intestinal contents and 0–24 h homogenized feces were ﬁrst
dissolved in 1 M NaOH before being counted for radioactivity. Rat
tissues and organs were homogenized and sampled (n ¼ 3, 100–
200 mg) before combustion by a Packard Sample Oxidizer (Mod-
el 307, PerkinElmer) and then sample radioactivity was counted
using Monophase S (PerkinElmer) as scintillation cocktail.
“Metabolite tracking” strategy (Figs. 2 and 3)
Metabolite tracking strategy has been previously used by our
group to study in vitro HNE metabolism in colon epithelial cells
[17,18]. In the present study, urine and feces coming from rats
treated with HNE were analyzed by HPLC–HRMS for twin peaks
tracking and identiﬁcation purpose and by radio-HPLC for quan-
tiﬁcation purpose. Urine was ﬁrst fully analyzed by HPLC–HRMS
and radio HPLC (Fig. 2, 1st set of experiment) but quantiﬁcation
and identiﬁcation results were difﬁcult to match on the basis of
retention time, due to slight differences between the two techni-
ques (even if the same column was used for chromatography). To
clarify and to conﬁrm our results, we undertook a second set of
experiments (Fig. 2), analyzing radio-HPLC collected fractions by
HRMS and MS/MS (Fig. 3). For feces samples, we only realized the
2nd set of experiments as metabolites concentrations were too
low to achieve a full analysis.
Radio-HPLC system
The system consisted of two HPLC Kontron 420 pumps (Kon-
tron, Selabo, France), managed with the HPLC software Diamir
(Varian Medical Systems, USA). The HPLC system was equipped
with a 500 ml loop and an Interchrom Strategy KR100 column C18
(5 mm, 4.6250 mm) (Interchim, France) kept in an oven ther-
mostated at 35 °C and connected to an on-line radioactivity ana-
lyzer (Packard Flo-one, Flow scintillation analyzer) using Flo-scint
as the scintillation cocktail or connected to a Gilson FC 204 fraction
collector (Gilson, France) for 4 tubes/min collection, using Packard
Ultima Gold as scintillation cocktail, when appropriate. Two mo-
bile phases were used. Mobile phase A containing: water/acet-
onitrile/acetic acid: 97.5/2.5/0.1; and mobile phase B containing:
Fig. 1. Labeling position of the HNE isotopes used for metabolite tracking and quantiﬁcation.
Fig. 2. Workﬂow for metabolites identiﬁcation and quantiﬁcation.
J. Keller et al. / Redox Biology 4 (2015) 136–148138water/acetonitrile/acetic acid: 40/60/0.1. Elution gradient was as
follows: 100% A from 0 to 4 min, a linear gradient from 4 to 20 min
from 0% to 6% B, a linear gradient from 20 to 25 min from 6% to
25% B, a plateau at 25% B from 25 to 35 min, a linear gradient from35 to 50 min from 25% to 90% B, a plateau at 90% B from 50 to
60 min.
Urine was injected directly whereas intestinal contents and 0–
24 h homogenized feces were extracted by 2 volumes of 0.5 M
Fig. 3. Work ﬂow of the 2nd set of experiments. Metabolites were identiﬁed using radio-HPLC separation, ‘twin peaks’ tracking by High Resolution Mass Spectrometry and
further ion fragmentation by MS/MS.
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HPLC–HRMS analysis (1st set of experiments)
Urine sample analysis was achieved using HPLC coupled to an
LTQ Orbitrap XL high-resolution mass spectrometer (Thermo,
Fisher Scientiﬁc, Les Ulis, France). Brieﬂy, 25 ml of urine was in-
jected into an HPLC system using the same column and the same
mobile phases and gradients as for radio-HPLC proﬁling, and a 1/4
post-column splitting HRMS acquisitions were performed using
electrospray ionization (ESI) in the negative mode with the fol-
lowing operating parameters: spray voltage (3.5 kV), heated
transfer capillary temperature (300 C), heated transfer capillary
voltage (1 V), tube lens voltage (50 V), sheath gas (N2) ﬂow
rate 40 au, auxiliary gas (N2) ﬂow rate 5 au. Full MS spectra were
recorded at a resolution of 30,000 from m/z 120–750.
Chromatograms for 0–6 h and 6–24 h urine and mass spectra
were analyzed for 0–6 h and 6–24 h urine and feces samples using
Xcalibur software (Thermo Scientiﬁc). Twin peaks were detected
on the basis of their m/z difference of 2.0067 a.m.u. corresponding
to similar chemical formula for 12Cn and 12C(n2)13C2 compounds
using the MetWorks software package (Thermo Scientiﬁc). The
search criteria for chemical formula determination were restricted
to a mass error below 5 ppm and C, H, O, N, S, P, K and Na were the
only accepted elements. Further MS/MS fragmentation was
achieved on twin peaks, for HNE metabolite identiﬁcation.
For MS/MS experiments, excitation parameters (isolation width(1.5 a.m.u.), normalized collision energy (35%), excitation time
(30 ms)) were adjusted in order to get maximum structural in-
formation for the compound of interest. When possible, high re-
solution was used (R¼7500) for fragment ion composition as-
signment. All analyses were achieved under automatic gain con-
trol conditions using helium as damping as well as collision gas for
MS/MS experiments.
HRMS and MS/MS infusion experiments (2nd set of experiments)
(Fig. 3)
Fractions of interest collected from urine and feces samples
were passed through a SPE cartridge. Obtained puriﬁed fractions
were evaporated under a nitrogen stream, and taken up by the
appropriate volume of methanol–water (50/50, v/v) to get a con-
centration of 1–5 ng/ml. Samples were infused at a ﬂow rate of 8 ml/
min into the LTQ Orbitrap XL high-resolution mass spectrometer.
The same mass spectrometry parameters as described above were
used for HRMS acquisitions and MS/MS experiments.Results and discussion
Radioactivity distribution
Radioactivity distribution was analyzed in the group treated
with 3H-HNE in urine, feces, intestinal contents and major organs
Fig. 4. Radioactivity distribution after 3H-HNE oral administration in rats (n¼3). Percentage of the given radioactivity found in 0–24 h urine and feces (A), intestinal contents
and tissues after 24 h (B) (volume or weight related).
J. Keller et al. / Redox Biology 4 (2015) 136–148140(Fig. 4). 24 h After radiolabeled HNE oral administration, most
radioactivity was found in urine (48%). 15% of the orally given dose
was found in feces. Around 3% was measured in the intestinal
contents (including 1.7% in cecum content) and around 2% in major
organs (including 1.5% in liver). Total radioactivity recovery was
68% knowing that this result is non-exhaustive given that only the
radioactivity in major organs was measured. In a previous study
done by our group on HNE metabolism following intra-venous
administration, 67% and 3% of the administered radioactivity was
found in urine and feces, respectively, 48 h after treatment [11].Fig. 5. Radio-HPLC proﬁles of 3H-HNE urinary metabolites after oral admUrinary HNE metabolites identiﬁcation and quantiﬁcation
First, we performed radio-HPLC analyses on urine collected
within 24 h after oral administration of 3H-HNE (Fig. 5A). Then, we
performed radio-HPLC analyses on urine collected over the ﬁrst
6 h after treatment and on urine collected between 6 and 24 h
after treatment (Fig. 5B and C).
On 0–24 h urine, a ﬁrst peak eluted at 3.1 min, then the major
peak eluted at 28.2 min, followed by a group of peaks eluting up to
33 min. Finally, a second group of peaks eluted between 41 andinistration in rats. A: 0–24 h urine. B: 0–6 h urine. C: 6–24 h urine.
Table 1
Metabolites identiﬁed in 0–24 h urine of rats treated with HNE.
Peak (% of urinary
radioactivity)
Ion m/z Fragments Proposed structure
From HNE from [13C]-HNE Chemical
formula
12C fragment
m/z ions
13C fragment
m/z ions
Fragment
interpretation
1 (2.07) 173.0456
175.0523
C7H9O5 155 [M–H–H2O] 7-Carboxy-4-hydroxy-hep-
tenoic acid137 [M–H–2H2O]
129 [M–H–COO]
111 [M–H–COO–H2O]
85 [M–H–COO–COO]
2 (2.20) 205.1082
207.1148
C9H17O5 187 [M–H–H2O] 4,8,9-Trihydroxy-nonanoic
acid169 [M–H–2H2O]
161 [M–H–COO]
145 [M–H–CHOH–CHOH]
3 (1.85) 185. 0821
187.0888
C9H13O4 167 169 [M–H–H2O] 9-Carboxy-HNE
141 143 [M–H–COO]
123 125 [M–H–COO–H2O]
4 (1.29) 201.0769
203.0836
C9H13O5 183 [M–H–H2O] 9-Carboxy-HNA
157 [M–H–COO]
139 [M–H–COO-H2O]
5 (0.23) 203.0926
205.0992
C9H15O5 185 [M–H–H2O] 9-Carboxy-4-Hydroxy-non-
anoic acid159 [M–H–COO]
141 [M–H–COO–H2O]
6 (26.72) 187.0977
189.1044
C9H15O4 169 171 [M–H–H2O] 9-Hydroxy-HNA
143 144 [M–H–COO]
113 114 [M–H–CHOH]
7 (3.74) 350.1281
352.1348
C14H24NO7S 332 334 [M–H–H2O] 9-Carboxy-DHN-MA
306 308 [M–H–COO]
221 223 [AþS]
162 162 [B]
128 128 [B–S]
364.1064
366.1136
C14H22NO8S 346 [M–H–H2O] 9-Carboxy-HNA-MA
320 [M–H–COO]
235 [AþS]
162 [B]
8 (1.25) 203.0020
205.0091
C9H15O5 185 [M–H–H2O] 8,9-Dihydroxy-HNA
172 [M–H–CHOH]
141 [M–H–COO–H2O]
121 [M–H–COO–2H2O]
9 (5.22) 185.0818
187.0882
C9H13O4 167 169 [M–H–H2O] 9-Oxo-HNA or 9-Hydroxy-
4-oxo-nonenoic acid141 142 [M–H–COO]
123 124 [M–H–COO–H2O]
348.1109
350.1177
C14H22NO7S 304 306 [M–H–COO] 9-Carboxy-HNE-MA
219 221 [AþS]
162 162 [B]
10 (2.14) 336.1486
338.1552
C14H26NO6S 207 209 [AþS] 9-Hydroxy-DHN-MA
189 191 [AþS–H2O]
159 160 [AþS–H2O–CHOH]
128 128 [B–S]
11 (2.35) 235.1035
237.1077
C10H19O4S 191 [M–H–COO] 3-Thiomethyl-9-Hydroxy-
HNA187 [M–H–S–CH3]
249.0803
251.0867
C10H17O5S 205 [M–H–COO] 3-Thiomethyl-9-Carboxy-
HNA201 [M–H–SCH3]
12 No twin peak
13 (1.46) 332.1172
334.1239
C14H22NO6S 203 205 [AþS] 9-Hydroxy-HNA-lactone-
MA162 162 [B]
346.0964
348.1031
C14H20NO7S 301 304 [M–H–COO] 9-Carboxy-HNA-lactone-
MA217 219 [AþS]
162 162 [B]
14 (1.10) 199.0598
201.0667
C9H11O5 181 183 [M–H–H2O] 9-Carboxy-4-oxo-none-
noique acid155 157 [M–H–COO]
137 139 [M–H–COO-H2O]
15 (4.38) 189.1132
191.1198
C9H17O4 171 [M–H–H2O] 4, (8 or 9)-Dihydroxy-non-
anoic acid129 [M–H–CH2COOH]
99
59 [CH2COOH]
16 (3.92) 189.1133
191.1199
C9H17O4 171 173 [M–H–H2O] 4, (8 or 9)-Dihydroxy-non-
anoic acid129 129 [M–H–CH2COOH]
59 61 [CH2COOH]
17 No twin peak
333.1554
335.1621
C15H25O8 193 193 Glucuronide 4-Glucuronide-DHN
157 159 [M–H-glucuronide]
347.1346 C15H23O9 193 193 Glucuronide 4-Glucuronide-HNA
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Table 1 (continued )
Peak (% of urinary
radioactivity)
Ion m/z Fragments Proposed structure
From HNE from [13C]-HNE Chemical
formula
12C fragment
m/z ions
13C fragment
m/z ions
Fragment
interpretation
349.1416
18 (6.53) 320.1539
322.1603
C14H26NO5S 191 193 [AþS] DHN-MA
128 128 [B–S]-
19 (6.98) 334.1331
336.1395
C14H24NO6S 290 292 [B–COO] HNA-MA
205 207 [AþS]
162 162 [B]
128 128 [B–S]
320.1539
322.1603
C14H26NO5S 191 193 [AþS] DHN-MA
128 128 [B–S]
20 (1.35) 318.1379
320.1445
C14H24NO5S 274 276 [B–COO] HNE-MA
189 191 [AþS]
171 173 [AþS–H2O]
162 162 [B]
334.1328
336.1396
C14H24NO6S 205 207 [AþS] HNA-MA
162 162 [B]
128 128 [B–S]
219.1064
221.1130
C10H19O3S 175 [M–H–COO] 3-Thiomethyl-HNA
171 [M–H–SCH3]
21 (4.31) 316.1225
318.1285
C14H22NO5S 162 162 [B] HNA–lactone-MA
J. Keller et al. / Redox Biology 4 (2015) 136–14814252.5 min. The analyzed peaks represent 88% of the urinary
radioactivity.
When 0–6 h urine was analyzed by radio-HPLC, the relative
abundance of the ﬁrst peak was very reduced compared to the
major peak. In contrast, in 6–24 h urine analysis, the ﬁrst peak
became one of the most important, whereas the relative abun-
dance of the major peak was greatly reduced.
Tritiated water
In radio-HPLC proﬁles we obtained from 0–24 h and 6–24 h rat
urine, a peak which retention time corresponded to the column
void volume was observed. This peak was not present when
samples were passed through a SPE cartridge. To tentatively
identify this peak, we have tested different methods, using eva-
poration or activated charcoal treatment of the SPE cartridge un-
retained fraction of urine. Activated charcoal added to the un-
retained fraction for 24 h, followed by ﬁltration on a Whatman GF/
A ﬁlter, did not decrease the radioactivity of the unretained frac-
tion. This result allowed us to identify this peak as tritiated water.
However, evaporation of this fraction led to a minor concentration
of radioactivity in the unretained fraction. This could be explained
by a weak enrichment of tritium, due to isotope discrimination
during water phase change [19].
Moreover, when organ samples were left for several hours for
drying purpose, an important loss of radioactivity (55%) was ob-
served, probably indicating tritiated water evaporation.
Tritiated water has been observed previously by our group
during radio-HPLC analysis of urine after intra-venous HNE
treatment [12] or of liver slices incubated with HNE [20]. It re-
presented 3.5% of 0–24 h urinary radioactivity and was completely
unretained by all kinds of SPE cartridge. Moreover, it was re-
covered in the condensate after evaporation. Other authors have
reported the presence of tritiated water in several in vitro and
in vivo 3H-HNE metabolic studies [21,22] but using tritiated HNE
with a different labeling position: [2-3H]-HNE compared to the
[4-3H]-HNE used in our group. These authors attributed the for-
mation of tritiated water to the ﬁrst step of β-oxidation of HNA.
Indeed, they reported a decrease of tritiated water formation by
the use of 4-pentaenoic acid, an inhibitor of β-oxidation [21]. In-
terestingly, a decrease in tritiated water following 4-pentaenoic
acid treatment was also observed in a study done in our group
with the tritium located on carbon 4, probably indicating furtherβ-oxidation steps [20]. The fact that in the present study, but also
in the previous studies done by our group [12,20], the formation of
tritiated water increased with time after dosing or incubation
time, indicates probably a multi-step process. Indeed, in the pre-
sent study, tritiated water accounted for 1.1% of urinary radio-
activity for 0–6 h urine, while it represented 15.9% of the urinary
radioactivity for the 6–24 h urine. Alary et al. [12] found no tri-
tiated water in the 0–2 h urine, 3.5% in the 2–24 h urine and 28% in
the 24–48 h urine, following intra-venous HNE treatment. More-
over, in the present study, tritiated water represented the major
radioactive peak in the intestinal contents 24 h following exposure
(Fig. 9). All together these results indicate an important catabolism
of HNE, given by oral or parenteral route, through β-oxidation of
HNA and possibly also through ω-oxidation of HNA and further β-
oxidation steps originating from the carbon 9 of HNA as recently
reported by some authors [23].
Other HNE metabolites identiﬁcation
Peak 1 eluted at 7.8 min (Fig. 5A). Using our metabolite tracking
technique with high resolution mass spectrometry for highlighting
HNE metabolites on the basis of their 12C/13C2 characteristic iso-
topic pattern, twin peaks were evidenced at m/z 173.0456
(12C7H9O5, calc. 173.0444, Δ¼0.5 ppm) and 175.0523
(12C513C2H9O5, calc. 175.0512, Δ¼0.5 ppm) (Table 1). High resolu-
tion accurate mass measurements allowed accessing elemental
composition of these ions, which were both in agreement with the
molecular formula C7H9O5. The MS/MS spectrum of the m/z 173
precursor ion exhibited 2 fragment ions corresponding to two
subsequent decarboxylations (m/z 129 and m/z 85 ions) that in-
dicated the presence of a dicarboxylic acid. On the basis of the
molecular formula and of this fragmentation pattern, peak 1 can
correspond to 7-carboxy-4-hydroxy-heptenoic acid. Such meta-
bolite has not been observed in our previous studies. This meta-
bolite could originate from a β-oxidation step originating from the
carbon 9 of HNA, as we observed the “twin compound” still re-
taining the stable isotope labeling on carbon 1 and 2 (ion at m/z
175), precluding any possibility of β-oxidation step on the carbons
1 and 2 of HNA. The presence of this metabolite accounting for 2%
of urinary radioactivity reinforces the HNE disposition pathway
evidenced recently by Jin et al. [23].
Peak 2 eluted at 16.5 min and accounted for 2.2% of urinary
radioactivity. Twin peaks at m/z 205.1086/207.1148, corresponding
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spectrum of the m/z 205 ion exhibited a fragment ion corre-
sponding to a decarboxylation (m/z 161 ion) and to the loss of a
terminal CH2OHCH2OH (m/z 145 ion). Based on these informa-
tion, the structure of 4,8,9-tri-hydroxy-nonanoic acid was tenta-
tively assigned to peak 2. Such chemical structure has not been
evidenced in our previous studies. However, ω1 oxidation has
been reported by Jin et al. [23].
Peak 3 eluted at 25.7 min and accounted for 1.85% of urinary
radioactivity. The C9H13O4 molecular formula could be deduced
from the twin peaks observed atm/z 185.0821/187.0888. MS/MS of
the m/z 185 ion exhibited a fragment ion corresponding to a dec-
arboxylation (m/z 141 ion). As the m/z 143 ion (and not m/z 142)
was observed following fragmentation of the m/z 187 twin pre-
cursor ion, it can be concluded that the decarboxylation did not
concern the labeled C1 carbon atom and that consequently the
carboxylic acid function is located at the carbon 9 position. ThisFig. 6. General fragmentation pattern and fragment ion notation of mercapturic
acid derivatives.
Fig. 7. Fragmentation mass spectra and interpretation for ions 187.0peak should then correspond to 9-carboxy-DHN.
The HNE metabolite tracking allowed us to tentatively identify
those minor peaks as new HNE metabolites.
Peak 4 eluted at 26.9 min and represented 1.3% of urinary
radioactivity. Twin peaks corresponding to the C9H13O5 molecular
formula were measured at m/z 201.0769/203.0836. The MS/MS
spectrum of the m/z 201 precursor ion exhibited major fragment
ions corresponding to dehydration and decarboxylation processes
(m/z 183, 157 and 139 fragment ions). This peak should then cor-
respond to 9-carboxy-HNA. Such a metabolite has been previously
observed in the rat, after intravenous administration [12] and in
mice after intraperitoneal treatment [24].
Peak 5 eluted at 27.6 min and represented 0.23 % of urinary
radioactivity and displayed twin peaks at m/z 203.0926/205.0992
corresponding to the C9H15O5 molecular formula. Similarly as for
peak 4, MS/MS carried out on the m/z 203 ion yielded a fragment
ions corresponding to dehydration and decarboxylation (m/z 185,
159 and 141 ions). This peak was then tentatively identiﬁed as
9-carboxy-4-hydroxy-nonanoic acid. This minor peak has not been
evidenced before.
Peak 6 was the major peak obtained on the radio-HPLC ana-
lysis; it eluted at 28.2 min and represented 27% of the urinary
radioactivity. Twin peaks were measured at m/z 187.0977
(12C9H15O4, calc. 187.0965, Δ¼0.7 ppm)/189.1044 (12C713C2H15O4,
calc. 189.1032, Δ¼0.6 ppm), allowing to propose C9H15O4 as mo-
lecular formula. The MS/MS spectrum of the m/z 187 ion exhibited
a fragment ion corresponding to a decarboxylation (m/z 143 ion,
Fig. 7). Opposite to what has been observed for Peak 3, an m/z 144
ion was observed following fragmentation of the m/z 189 twin977 (12C-HNE metabolite) and 189.1044 (13C-HNE metabolite).
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that the decarboxylation involved the labeled C1 carbon atom of
the metabolite. Consecutive losses of 30 a.m.u. (m/z 113 and 114
fragment ions) from both m/z 143 and 144 ions indicated the
presence of a CH2OH moiety in the terminal position. Moreover,
this peak coeluted with 9-hydroxy-HNA standard. This allowed us
to identify this metabolite as 9-hydroxy-HNA. As for 9-carboxy-
HNA, 9-hydroxy-HNA has been observed in urine of rats and mice
after parenteral HNE administration. Such terminal oxidation
process could involve cytochrome P450 4A family because ﬁbrate
treated mice excreted more of those compounds than untreated
ones, or than PPARα-deﬁcient and ﬁbrate treated ones [12,24].
Cytochrome P450 4A enzymes speciﬁcally catalyze the ω- and
ω1-hydroxylation of medium and long chain fatty acids [25].
The presence of 9-hydroxy-HNA as a major metabolite in the
present study indicated a prominent role of cytochrome P450 4A
family in HNE metabolization after oral administration.
Peak 7 was not fully resolved from Peak 6. It eluted at 28.9 min
and represented approximately 4% of urinary radioactivity. How-
ever, this peak revealed the occurrence of two pairs of twin peaks.
The ﬁrst pair of ions at m/z 350.1281/352.1348 (molecular formula
C14H24NO7S) gave upon fragmentation the characteristic fragment
ions of a mercapturic acid conjugate at m/z 162 [B] and of and m/
z 128 [BS] (see Fig. 6 for fragment notation of mercapturic acid
derivatives). MS/MS fragmentation of the pair of m/z 350/352 ions
also yielded fragment ions corresponding to a decarboxylation (m/
z 306/308 ions), indicating that this decarboxylation should be on
the carbon 9 as it was the case for Peak 3. Intense fragment ions of
were observed at m/z 221/223 and corresponded to [AþS]
fragments. Taken together, those results indicated that this meta-
bolite should be identiﬁed as 9-carboxy-DHN-MA. The second pair
of twin ions was detected at m/z 364.1069/366.1136, and gave
upon fragmentation almost the same fragment ions as the pre-
vious pair, with a mass difference of 14 a.m.u., which could be
attributed to the occurrence of a COOH group instead of a CH2OH
group. This metabolite could then be identiﬁed as 9-carboxy-HNA-
MA. Mercapturic acids derivatives of ω-oxidized HNE metabolites
have been identiﬁed previously in rat urine, after intravenous
administration [12]. Mercapturic acid metabolites derive from
conjugation of the parent compound to glutathione, catalyzed by
glutathione S-transferases, and the subsequent metabolization of
the glutathione moiety into mercapturic acid [26].
Peak 8 eluted at 29.3 min and represented 1.25% of urinary
radioactivity. Twin peaks were detected atm/z 203.0020/205.0091,
in agreement with a C9H15O5 molecular formula, as observed for
Peak 5. However, the MS/MS fragmentation of this metabolite was
quite different to that of Peak 5. Opposite to Peak 5, this peak gave
an m/z 173 fragment ion characteristic of the elimination of CH2O
from a CH2OH group present in the terminal position. Accordingly,
this peak should then correspond to 8,9-dihydroxy-HNA.
Peak 9 eluted at 29.6 min and represented 5.2% of urinary
radioactivity. Exact mass measurements revealed the occurrence
of two pairs of twin peaks. The ﬁrst pair was observed at m/z
185.0818/187.0882 (C9H13O4), as for Peak 3. However, as for Peak 6,
the MS/MS spectra of this compound showed a loss of 44 a.m.u.
(yielding the m/z 141 fragment ion) from the m/z 185 precursor ion
whereas a loss of 45 a.m.u. (yielding the m/z 142 fragment ion)
occurred from the m/z 187 precursor ion, indicating that these
fragment ions originated in a decarboxylation occurring on carbon
1. This metabolite should then correspond to 9-oxo-HNA. How-
ever, a structure corresponding to 9-hydroxy-4-oxo-HNA could
also be in agreement with the mass spectrometric data. The sec-
ond pair of twin peaks was observed at m/z 348.1109/350.1177
(C14H22NO7S). As for Peak 7, this metabolite gave upon fragmen-
tation the characteristic m/z 162 [B] ion of a mercapturic acid
conjugate. MS/MS fragmentation of the m/z 348/350 ions exhibitedfragment ions corresponding to a decarboxylation (m/z 304/306
ions) indicating that this decarboxylation should take place on the
C9 carbon atom (loss of 44 a.m.u. for both m/z 348 and 350 pre-
cursor ions). These results allowed the identiﬁcation of this me-
tabolite as 9-carboxy-HNE-MA.
Peak 10 eluted at 30.5 min and represented 2.1% of urinary
radioactivity, and presented twin peaks at m/z 336.1486/338.1552
(C14H26NO6S). Fragment ions corresponding to [BS] (m/z 128)
and to [AþS] (m/z 207/209) were observed in MS/MS, allowing
to identify peak 10 as a mercapturic acid conjugate. Consecutive
water and alcohol group losses from the 207/209 ions, respec-
tively, led to the 189/191 and 159/160 fragment ions, in accordance
with a loss of the labeled alcohol group on the C1 carbon atom.
This metabolite was thus identiﬁed as hydroxy-DHN-MA, the
other alcohol group likely being located on the C9 carbon atom.
Radioactivity between Peak 10 and 12 (named 11 in Fig. 5A)
corresponded to 2.3% of urinary radioactivity. Two pairs of twin
peaks could be detected at m/z 235.1011/237.1077 and 249.0803/
251.0867 giving both, upon fragmentation, fragment ions corre-
sponding respectively to a CO2 loss (44 a.m.u.) and to a methyl-
thiol group loss (48 a.m.u.). Both elemental compositions de-
duced from exact mass measurements and MS/MS fragmentation
data allowed us to identify these metabolites as 9-hydroxy-3-
thiomethyl-HNA and 3-thiomethyl-carboxy-HNA. Those metabo-
lites were seen only in the 6–24 h urine, indicating either several
steps in their formation or the intervention of microbial ﬂora in
the distal part of the intestine. This is, to our knowledge, the ﬁrst
report of thiomethyl metabolites of HNE. Their formation could
arise from two putative ways. The ﬁrst one could involve the ac-
tion of hydrogen sulﬁde (H2S) which is known to be a metabolic
product of intestinal ﬂora and is present in its free form in the
distal parts of the intestine (for a review, see [27]). Hydrogen
sulﬁde has been reported to scavenge HNE in vitro in neuronal cell
culture and to prevent HNE adduction to cellular proteins [28].
This thiol compound could then be methylated by thiol S-me-
thyltransferases in the intestine, as colon and cecal mucosa are
believed to be major sites of thiol methylation [29]. The second
one could involve the so-called mercapturic acid shunt. Most of
the time, glutathione conjugates are transformed into mercapturic
acids by two subsequent reactions, namely the cleavage of the γ-
glutamyl bond of the glutathione moiety, leaving a thioether of
cysteine, which is N-acetylated, forming a mercapturic acid deri-
vative readily excreted into urine. In the mercapturic acid shunt,
the cysteine conjugate is subjected to β-lyase action, giving a thiol
compound, which can be methylated by thiol S-methyl-
transferases. β-Lyases from microbiota present in the distal parts
of the intestine may play an important role in this process [30].
Peak 12 revealed no interpretable mass spectrometry signal,
despite the presence of radioactivity detected at this retention
time.
Peak 13 eluted at 38.5 min and represented 1.5% of urinary
radioactivity. This peak was also a mixture of two pairs of twin
peaks at m/z 332.1172/334.1239 and 346.0964/348.1031, respec-
tively. Both pairs presented, upon fragmentation, the [B] (m/z
162) and [AþS] (m/z 203/205 and 217/219) ions characteristic of
mercapturic acid conjugates. Under MS/MS, the m/z 346/348 pair
also gave the m/z 302/304 fragment ions, corresponding to the
elimination of CO2 from the C9 carbon atom. Those compounds
were thus respectively identiﬁed as 9-hydroxy-HNA–lactone-MA
(although the position of the hydroxyl group on carbon 9 cannot
be conﬁrmed), and 9-carboxy-HNA–lactone-MA.
Peak 14 eluted at 41.1 min and represented 1.1% of urinary
radioactivity. High resolution MS analysis revealed only one pair of
twin peaks at m/z 199.0598/201.0667 with a molecular formula of
C9H11O5. Fragment ions corresponding to a decarboxylation on the
C9 carbon atom (m/z 155/157 ions) were observed, enabling to
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However, as this metabolite should have lost the tritium on carbon
4, the radioactive peak should correspond to another metabolite
that could not be characterized by LCMS.
Peak 15 and 16 eluted at 42.1 and 42.7 min and represented
4.38% and 3.9% of urinary radioactivity, respectively. For both of
them, MS analysis gave a pair of twin peaks at m/z 189.1132(3)/
191.1198(9) (Table 1) in agreement with a C9H17O4 chemical for-
mula. The MS/MS analysis revealed the presence of a fragment ion
atm/z 129 for both metabolites and both twin peaks, together with
the complementary twin fragment ions at m/z 59/61, indicating
the loss of a CH3COOH group on carbon 1 (Fig. 8). Taken together,
these results indicate the presence of hydroxylated 4-hydroxy-
nonanoic acid. The presence of two radioactive peaks suggests the
occurrence of two region-isomers bearing the hydroxyl group on
two different positions (likely on C9 for one metabolite and on C8
for the other). It is noteworthy that the fragmentation pattern is
quite different from the one of hydroxylated-HNA (Peak 6) for
which a loss of 44 a.m.u. (CO2) instead of 60 a.m.u. (CH3COOH) was
observed, probably due to the presence of the double bond be-
tween C2 and C3, precluding any fragmentation at this location.
Those peaks were thus tentatively identiﬁed as 4,8-hydroxy-non-
anoic acid and 4,9-hydroxy-nonanoic acid. Those metabolites are
the saturated counterparts of hydroxy-HNA. Reduction of the HNE
double bond has previously been described by our group in in
vitro studies performed on colonocytes. It was followed by an
oxidation of the aldehyde function [17]. This saturation pathway
could involve NADPH-dependent alkenal/one oxidoreductase as
reported by some authors [31]. 4,8-Hydroxy-nonanoic acid and
4,9-hydroxy-nonanoic acid have been reported by Jin et al. [23]
and by Laurent et al. [20], as metabolites of HNE.Fig. 8. Fragmentation mass spectra and interpretation for ions 189.Peak 17 revealed no interpretable mass spectrometric signal.
Radioactivity between peak 17 and peak 18 gave two pairs of twin
peaks, at m/z 333.1554/335.1621, 347.1346/349.1416 giving either a
fragment ion at m/z 193 or fragment ions corresponding to a loss
of 176 a.m.u. All these features can be considered as characteristic
of glucuronidated metabolites [32]. Twin peaks atm/z 333/335 and
at 347/349 should then correspond to DHN–glucuronide and
HNA–glucuronide, respectively, with a respective chemical for-
mula of C15H25O8 and C15H23O9. To our knowledge, this is the ﬁrst
report of glucuronide conjugates as metabolites of HNE.
Peak 18 and 19 eluted at 47.0 and 47.3 min and represented
respectively 6.5% and 7% of urinary radioactivity. They both re-
vealed twin peaks at m/z 320.1539/322.1603 (C14H26NO5S) upon
high resolution MS analysis, with a common fragment ion at m/z
128 and twin fragments at 191/193, characteristic of the mercap-
turic acid of DHN. DHN-MA has been reported by our group to be
the major HNE metabolite after intravenous administration [11].
The present study showed that DHN-MA, although being quanti-
tatively an important HNE metabolite, was not the major one after
oral administration. This can be attributed to the important oxi-
dative metabolism observed by our group in vitro in intestinal
epithelial cells [17]. In Peak 19, we observed the concomitant
presence of a twin peak at m/z 334.1331/336.1395 (C14H24NO6S)
giving in MS/MS a twin fragment of m/z 290/292 characteristic of
the loss of a carboxylate group (not located on the C1 carbon
atom), together with the presence of characteristic fragment ions
of a mercapturic acid conjugate, indicating the presence of HNA-
MA in this radioactive peak.
Peak 20 eluted at 48.7 min and represented 1.35% of urinary
radioactivity. This peak exhibited two pairs of twin peaks at
m/z 318.1379/320.1445 (C14H24NO5S) and 334.1328/336.13961132 (12C-HNE metabolite) and 191.1198 (13C-HNE metabolite).
Fig. 9. Cecal radio-HPLC proﬁle at 24 h (A) and fecal 0–24 h radio-HPLC proﬁle (B) of rats treated with HNE.
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and 128 that are characteristic of mercapturic acid conjugates and
twin fragment ions at m/z 189/191 and m/z 205/207, respectively
corresponding to the complementary ions of [HNEþS] and
[HNAþS] , conﬁrming the presence of HNE-MA and HNA-MA.
This peak co-eluted with HNA-MA standard.
Analyses carried out between Peak 20 and 21 revealed the
presence of twin peaks at m/z 219.1064/221.1130 (C10H19O3S)
indicating the presence of a sulfur atom in the molecule.
Fragmentation of the m/z 219 ion gave daughter ions at m/z 175
and m/z 171 that were respectively attributed to the loss of a
carboxylic group and of a thiomethyl group respectively, indicating
that this compound could correspond to a thiomethyl derivative of
HNA.Peak 21 eluted at 52.7 min and represented 4.31% of urinary
radioactivity. MS analysis revealed twin peaks at m/z 316.1225/
318.1285 (C14H22NO5S) both giving upon fragmentation an intense
peak at m/z 162, characteristic of a mercapturic acid. This frag-
mentation is in accordance with the presence of HNA–lactone-MA.
DHN-MA, HNE-MA, HNA-MA, HNA–lactone-MA are expected
urinary metabolites that have been observed in most in vivo stu-
dies done on HNE metabolism [11,13]. Some of them, such as
DHN-MA, are used as lipid peroxidation biomarkers [33,34].
Intestinal contents and feces analyses
We also analyzed by radio-HPLC intestinal contents (stomach,
small intestine, cecum and colon) and feces.
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contents and feces radio-HPLC proﬁles displayed an important
peak with an early retention time. As demonstrated earlier, this
peak was identiﬁed as tritiated water.
In intestinal contents, it was clearly the major peak, re-
presenting between 50% and 71% of the radioactivity in the sample
(Fig. 9A).
In contrast, tritiated water represented only 16% of the total
radioactivity in feces (Fig. 9B). It could be explained by the fact
that an important part of the water present in intestinal contents
is reabsorbed in the colon.
Four other groups of peaks could be determined at 17.2 min,
28.6 min, 42.9 min and 52.2 min.
In order to attempt to identify those fecal metabolites, we
performed HRMS and MS/MS analyses of radio-HPLC collected
fractions. Unfortunately, no twin peaks were identiﬁed in those
samples, probably because of the necessary concentration/eva-
poration steps before MS/MS analyses, due to low concentration of
metabolites in the samples studied.Conclusion
The metabolite tracking methodology allowed the speciﬁc
identiﬁcation of HNE urinary metabolites and gave valuable in-
sights into chemical function positions. All together these results
indicate a prominent role of oxidation pathways, on carbon
1 bearing the aldehyde function and also on the terminal carbon,
in the metabolization of HNE after oral administration. These ﬁrst
oxidation steps are most probably followed by β-oxidation steps
originating from the carbon 1 and/or 9 of HNA and ﬁnally the
production of water. Those pathways are quantitatively more im-
portant than the mercapturic acid pathway with more than 50% of
total urinary radioactivity, while mercapturic conjugates represent
around 30% of urinary radioactivity. Those oxidation pathways
underline the importance of aldehyde dehydrogenase (ALDH) and
of cytochrome P450 4A enzyme families in the respective oxida-
tion of the HNE aldehyde function on carbon 1 and the terminal
oxidation on carbon 9. As a consequence of those prominent oxi-
dative pathways involved in HNE metabolization after oral ad-
ministration, DHN-MA did not represent the major urinary me-
tabolite as reported after intravenous administration [11]. The
huge excretion of this metabolite after a heme-iron rich diet in
rats, almost 10 mg/24 h, shows that important quantities of HNE
can be absorbed and be metabolized, and could also be related to
promotion of colon carcinogenesis [33,35].
The metabolite tracking methodology allowed also to speciﬁ-
cally detect quantitatively novel minor HNE urinary metabolites
such as thiomethyl and glucuronide derivatives. Studies are under
progress to determine if those metabolites are speciﬁc of an oral
administration, and in the case of the HNA-thiomethyl metabo-
lites, if their parent thiol compounds could bear some toxicity.Conﬂict of interest
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